학술논문
Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Document Type
Abstract
Author
Source
In Blood 23 November 2021 138 Supplement 1:3846-3846
Subject
Language
ISSN
0006-4971